vs
Alignment Healthcare, Inc.（ALHC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Alignment Healthcare, Inc.的季度营收约是Revvity的1.6倍（$1.2B vs $772.1M），Revvity净利率更高（12.7% vs 0.9%，领先11.8%），Revvity同比增速更快（5.9% vs -74.7%），过去两年Alignment Healthcare, Inc.的营收复合增速更高（34.6% vs 9.0%）
Alignment Healthcare是总部位于美国的医疗保健企业，主打联邦医疗保险优势计划，为老年群体提供协调医疗服务、处方药保障及补充福利，采用价值导向医疗模式，与本土医疗机构合作，业务覆盖美国多个州，致力提升患者健康水平。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ALHC vs RVTY — 直观对比
营收规模更大
ALHC
是对方的1.6倍
$772.1M
营收增速更快
RVTY
高出80.6%
-74.7%
净利率更高
RVTY
高出11.8%
0.9%
两年增速更快
ALHC
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $11.4M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 0.9% | 12.7% |
| 营收同比 | -74.7% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALHCRVTY
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.0B | $772.1M | ||
| Q3 25 | $993.7M | $698.9M | ||
| Q2 25 | $1.0B | $720.3M | ||
| Q1 25 | $926.9M | $664.8M | ||
| Q4 24 | $701.2M | $729.4M | ||
| Q3 24 | $692.4M | $684.0M | ||
| Q2 24 | $681.3M | $691.7M |
净利润ALHCRVTY
| Q1 26 | $11.4M | — | ||
| Q4 25 | $-11.0M | $98.4M | ||
| Q3 25 | $3.7M | $46.7M | ||
| Q2 25 | $15.7M | $53.9M | ||
| Q1 25 | $-9.1M | $42.2M | ||
| Q4 24 | $-31.1M | $94.6M | ||
| Q3 24 | $-26.4M | $94.4M | ||
| Q2 24 | $-24.0M | $55.4M |
毛利率ALHCRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率ALHCRVTY
| Q1 26 | — | — | ||
| Q4 25 | -1.0% | 14.5% | ||
| Q3 25 | 0.8% | 11.7% | ||
| Q2 25 | 2.2% | 12.6% | ||
| Q1 25 | -0.6% | 10.9% | ||
| Q4 24 | -3.2% | 16.3% | ||
| Q3 24 | -2.8% | 14.3% | ||
| Q2 24 | -2.7% | 12.4% |
净利率ALHCRVTY
| Q1 26 | 0.9% | — | ||
| Q4 25 | -1.1% | 12.7% | ||
| Q3 25 | 0.4% | 6.7% | ||
| Q2 25 | 1.5% | 7.5% | ||
| Q1 25 | -1.0% | 6.4% | ||
| Q4 24 | -4.4% | 13.0% | ||
| Q3 24 | -3.8% | 13.8% | ||
| Q2 24 | -3.5% | 8.0% |
每股收益（稀释后）ALHCRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-0.04 | $0.86 | ||
| Q3 25 | $0.02 | $0.40 | ||
| Q2 25 | $0.07 | $0.46 | ||
| Q1 25 | $-0.05 | $0.35 | ||
| Q4 24 | $-0.15 | $0.77 | ||
| Q3 24 | $-0.14 | $0.77 | ||
| Q2 24 | $-0.13 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $705.6M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $206.9M | $7.3B |
| 总资产 | $1.3B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALHCRVTY
| Q1 26 | $705.6M | — | ||
| Q4 25 | $604.2M | $919.9M | ||
| Q3 25 | $644.1M | $931.4M | ||
| Q2 25 | $503.8M | $991.8M | ||
| Q1 25 | $479.5M | $1.1B | ||
| Q4 24 | $470.6M | $1.2B | ||
| Q3 24 | $381.0M | $1.2B | ||
| Q2 24 | $363.7M | $2.0B |
总债务ALHCRVTY
| Q1 26 | — | — | ||
| Q4 25 | $323.2M | — | ||
| Q3 25 | $322.7M | — | ||
| Q2 25 | $322.3M | — | ||
| Q1 25 | $321.9M | — | ||
| Q4 24 | $321.4M | — | ||
| Q3 24 | $212.0M | — | ||
| Q2 24 | $211.7M | — |
股东权益ALHCRVTY
| Q1 26 | $206.9M | — | ||
| Q4 25 | $179.3M | $7.3B | ||
| Q3 25 | $161.9M | $7.4B | ||
| Q2 25 | $141.0M | $7.6B | ||
| Q1 25 | $108.1M | $7.6B | ||
| Q4 24 | $99.9M | $7.7B | ||
| Q3 24 | $114.5M | $7.9B | ||
| Q2 24 | $123.7M | $7.9B |
总资产ALHCRVTY
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.1B | $12.2B | ||
| Q3 25 | $1.1B | $12.1B | ||
| Q2 25 | $1.0B | $12.4B | ||
| Q1 25 | $895.6M | $12.4B | ||
| Q4 24 | $782.1M | $12.4B | ||
| Q3 24 | $692.3M | $12.8B | ||
| Q2 24 | $716.3M | $13.4B |
负债/权益比ALHCRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.80× | — | ||
| Q3 25 | 1.99× | — | ||
| Q2 25 | 2.29× | — | ||
| Q1 25 | 2.98× | — | ||
| Q4 24 | 3.22× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.71× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $128.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 11.27× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ALHCRVTY
| Q1 26 | $128.7M | — | ||
| Q4 25 | $-50.4M | $182.0M | ||
| Q3 25 | $144.6M | $138.5M | ||
| Q2 25 | $29.1M | $134.3M | ||
| Q1 25 | $16.6M | $128.2M | ||
| Q4 24 | $-8.7M | $174.2M | ||
| Q3 24 | $26.2M | $147.9M | ||
| Q2 24 | $23.5M | $158.6M |
自由现金流ALHCRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-55.4M | $161.8M | ||
| Q3 25 | $139.1M | $120.0M | ||
| Q2 25 | $21.1M | $115.5M | ||
| Q1 25 | $8.4M | $112.2M | ||
| Q4 24 | $-18.0M | $149.8M | ||
| Q3 24 | $16.9M | $125.6M | ||
| Q2 24 | $11.8M | $136.6M |
自由现金流率ALHCRVTY
| Q1 26 | — | — | ||
| Q4 25 | -5.5% | 21.0% | ||
| Q3 25 | 14.0% | 17.2% | ||
| Q2 25 | 2.1% | 16.0% | ||
| Q1 25 | 0.9% | 16.9% | ||
| Q4 24 | -2.6% | 20.5% | ||
| Q3 24 | 2.4% | 18.4% | ||
| Q2 24 | 1.7% | 19.7% |
资本支出强度ALHCRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 2.6% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 0.8% | 2.6% | ||
| Q1 25 | 0.9% | 2.4% | ||
| Q4 24 | 1.3% | 3.4% | ||
| Q3 24 | 1.3% | 3.3% | ||
| Q2 24 | 1.7% | 3.2% |
现金转化率ALHCRVTY
| Q1 26 | 11.27× | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | 38.77× | 2.97× | ||
| Q2 25 | 1.86× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALHC
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
